The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | The impact of lung cancer screening on patients and clinicians
David Yankelevitz, MD, Mount Sinai School of Medicine, New York, NY, outlines the perceived clinical benefit of lung cancer screening. Referring clinicians and screening participants were interviewed to investigate their understanding of the extent of benefit in the screening programme. The survey revealed that both parties believed lung cancer screening was more or as important than other programmes, such as prostate and colon screening. Patients reported that they did not need to understand the clinical benefit to participate in screening, but clinicians found the concept confusing. Prof. Yankelevitz suggested that clinicians have a strong impact on the uptake in lung cancer screening, hence it is important to communicate the benefit of the programme in a more coherent way. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
